Top

Reactions Weekly

Published in:

01-02-2024 | Entrectinib | Case report

Entrectinib/gimeracil/oteracil/tegafur

Lack of efficacy, off-label use and various toxicities

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Moriyama E, et al. A case of complete response to entrectinib in NTRK fusion gene-positive parotid carcinoma. Annals of Oncology 34 (Suppl. 3): S1457-S1458 abstr. P43-3, Nov 2023. Available from: URL: https://dx.doi.org/10.1016/j.annonc.2023.09.390 [abstract]

Title: Entrectinib/gimeracil/oteracil/tegafur
Lack of efficacy, off-label use and various toxicities
Publication date: 01-02-2024
Publisher: Springer International Publishing
Keywords: Entrectinib
Taste Disorder
Fatigue
Metastasis
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-53553-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Entrectinib/gimeracil/oteracil/tegafur

Lack of efficacy, off-label use and various toxicities

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Bleomycin

Etanercept

Multiple drugs

Valproate

Pantoprazole

Multiple drugs